Medicare Advantage Has a 12-Month Trial Period With a Full Escape Hatch. Almost Nobody Uses It in Time.

Photo of Gerelyn Terzo
By Gerelyn Terzo Published

Quick Read

  • Medicare Advantage enrollees get one 12-month trial right to return to Original Medicare and buy a guaranteed-issue Medigap policy without medical underwriting.

  • The trial window closes 63 days after year one ends, and missing it can permanently expose beneficiaries to unlimited 20% outpatient coinsurance with no cap.

  • The MA Open Enrollment Period, which runs from January through March, lets you leave Advantage but does not guarantee Medigap access, leaving post-year-one switchers vulnerable to health underwriting.

  • Many financial professionals are salespeople paid on what they push, not whether you end up wealthier. A fiduciary is the opposite. The SEC legally requires them to put your interests first. Advisor.com's free matching tool pairs you with vetted fiduciaries from major national firms, all in under three minutes. See who you match with today.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Medicare Advantage Has a 12-Month Trial Period With a Full Escape Hatch. Almost Nobody Uses It in Time.

© Inna Kot / Shutterstock.com

A 66-year-old retiree signs up for a zero-premium Medicare Advantage plan the month she turns 65. Fourteen months in, her orthopedist drops the network, her prior authorization for an MRI is denied twice, and she wants back on Original Medicare with a Medigap policy. She calls a broker. The broker asks when she first enrolled. Then he tells her the escape hatch closed 60 days ago.

This is the Medicare Advantage trial right, and it is one of the most valuable one-time protections in Medicare, as well as one of the easiest to miss. If you are already past your first year in an Advantage plan, your trial window may have closed unless another guaranteed-issue protection applies. If you are in your first 12 months, or about to enroll, read on.

What the Trial Right Actually Does

Federal law gives two separate 12-month trial rights to drop a Medicare Advantage plan, go back to Original Medicare, and buy a guaranteed-issue Medigap policy with no medical underwriting. That last phrase is the whole ballgame. Outside of these windows, in most states, a Medigap insurer can look at your health, charge you more, or refuse you outright.

The two versions:

Trial Right 1: You enrolled in a Medicare Advantage plan (or PACE) the first time you were eligible for Medicare at 65. You have 12 months from your MA effective date to drop it and buy any Medigap policy sold in your state, guaranteed issue.

Trial Right 2: You had Original Medicare plus a Medigap policy, then switched to Medicare Advantage for the first time ever. You have 12 months to switch back, and you can return to your prior Medigap policy if the same insurer still sells it. If not, you may buy one of several federally specified Medigap plans from another carrier.

Both rights impose a strict application window: no earlier than 60 calendar days before your MA coverage ends, and no later than 63 days after. Miss the 63-day tail and the guarantee can evaporate.

The Trap Hiding Inside a Familiar Window

The Medicare Advantage Open Enrollment Period runs January 1 to March 31 every year. It looks like the escape hatch, but it works differently. The MA OEP lets any current Advantage enrollee drop the plan and return to Original Medicare with a standalone Part D drug plan. What it does not do is guarantee you a Medigap policy. That guarantee only comes from a trial right or another qualifying circumstance.

So a healthy 68-year-old in her third year of Advantage can use the MA OEP to leave her plan in March and land on Original Medicare in April, then discover that Medigap carriers in her state want health questionnaires and her recent knee surgery puts coverage out of reach. The exit worked. The supplement did not.

The Real Cost of Missing It

Original Medicare has no annual out-of-pocket maximum by itself. Part B has a standard monthly premium of $202.90 in 2026 and a $283 annual deductible, after which the beneficiary generally owes 20% of covered outpatient costs with no ceiling. Medigap Plan G covers most of that cost-sharing after the Part B deductible, but only if you can buy one. Once medical underwriting kicks in, a person with conditions such as diabetes with complications, recent cancer treatment, or congestive heart failure may be charged more or denied coverage altogether.

Four states currently loosen this math, but not equally. Connecticut and New York provide continuous guaranteed-issue access. Massachusetts requires an annual window, although its insurers currently offer year-round enrollment. Maine requires insurers to offer Plan A during one month each year. Minnesota is scheduled to add an annual enrollment window in August 2026.

Elsewhere, federal law provides a six-month Medigap open enrollment period beginning when someone is 65 or older and enrolled in Part B. The trial right can serve as a crucial second chance, although some states offer additional protections of their own.

What to Do Now

  • If you enrolled in Medicare Advantage within the last 12 months under either trial-right scenario and have doubts about the plan, calendar your deadline today. The clock runs from your MA effective date, not your birthday. Apply for the Medigap policy between 60 days before and 63 days after your intended MA drop date, and do not let the tail expire.
  • If you are choosing Advantage for the first time at 65, treat the decision as harder to reverse than the marketing suggests. The trial right protects year one. Years two and beyond, unless another federal or state protection applies, may put you at the mercy of an underwriter.

Check your state’s Medigap rules before you assume the federal floor applies. A 10-minute call to your State Health Insurance Assistance Program (SHIP) is free and can answer that question precisely.

Contact [email protected] for any questions or corrections.

Photo of Gerelyn Terzo
About the Author Gerelyn Terzo →

Gerelyn Terzo is the author of dividend investing handbook "Dividend Investing Strategies: How to Have Your Cake & Eat It Too." A veteran financial journalist, she covers agri-finance for outlets like Global AgInvesting and the broader stock market and personal finance for 24/7 Wall Street. She began at CNBC and later helped launch Fox Business in New York. Gerelyn currently resides in Woodland Park, Colorado and dabbles in nature photography as a hobby.

Continue Reading

Top Gaining Stocks

IP Vol: 11,975,298
SLB Vol: 28,901,066
DLR Vol: 10,764,777
PKG Vol: 1,424,156
NOW Vol: 29,625,381

Top Losing Stocks

CHRW Vol: 3,602,159
CTRA Vol: 73,319,495
INTC Vol: 181,129,771
WST Vol: 1,508,636
MU Vol: 40,804,475